T2 Biosystems (NSDQ:TTOO) yesterday said it appointed John Sperzel as president and CEO, effective immediately.
Sperzel succeeds John McDonough who will continue to serve on the board as a non-executive chairman.
“I am honored to join T2 Biosystems as its second CEO at this important transitional moment,” Sperzel said in a news release. “This is an exciting time for the company, in the battle against sepsis, and I look forward to leading the business to its next chapter of growth. Sepsis represents $27 billion in annual U.S. healthcare costs and claims more lives annually than lung cancer, colorectal cancer and breast cancer combined. T2 Biosystems has the only FDA-cleared diagnostic tests to detect sepsis-causing pathogens directly from whole blood, which can save lives, reduce healthcare costs and fight antimicrobial resistance.”
Prior to joining T2 Biosystems, Sperzel served as president and CEO of Chembio Diagnostics. He has also served as president and CEO of ITC Medical and held a number of leadership roles at Axis-Shield (Abbott), Bayer Diagnostics (Siemens), Instrumentation Laboratory and Boehringer Mannheim (Roche).
“We are thrilled to welcome John as president and CEO at T2 Biosystems,” McDonough said. “John’s leadership, passion and deep commercial experience make him well-suited to lead the company through a stage of rapid growth. We look forward to working with John and the senior leadership team to bring our novel technology to more clinicians so they can do what matters most – save lives.”